ABVX Abivax SA

DGAP-News: Abivax 2021 Financial Communication Calendar

DGAP-News: ABIVAX / Key word(s): Miscellaneous
Abivax 2021 Financial Communication Calendar

03.12.2020 / 18:00
The issuer is solely responsible for the content of this announcement.

Abivax 2021 Financial Communication Calendar


PARIS, FRANCE, December 3, 2020 - 6:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today publishes its 2021 financial communication calendar.

  • Thursday, April 1, 2021
    Publication of financial statements as of December 31, 2020
     
  • Friday, April 30, 2021
    Publication and release of the 2020 annual financial report
     
  • Friday, June 4, 2021 - 10.00 a.m.
    Shareholders meeting
     
  • Thursday, September 23, 2021
    Publication of financial statements as of June 30, 2021
     
  • Thursday, September 30, 2021
    Publication and release of 2021 half year report


About Abivax ()
Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at . Follow us on Twitter @ABIVAX_.


Contacts

Abivax
Communications
Regina Jehle

63		 Investors
LifeSci Advisors
Chris Maggos

 Press Relations & Investors Europe
MC Services AG
Anne Hennecke

22
Public Relations France
Actifin
Ghislaine Gasparetto

24		 Public Relations France
DGM Conseil
Thomas Roborel de Climens

84		 Public Relations USA
Rooney Partners LLC
Marion Janic

03.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

1152398  03.12.2020 

fncls.ssp?fn=show_t_gif&application_id=1152398&application_name=news&site_id=research_pool
EN
03/12/2020

Underlying

ABVXAbivax SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abivax SA

 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimo...

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel diseaseAnti-fibrotic effects of obefazimod were observed in both a ...

20h / 57m 1 EN
Free Trial
ABVX ABIVAX SA

Abivax: 1 director

A director at Abivax sold 1,000,000 shares at 122.334USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

01/16/26 January 16, 2026 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Provides 2026 Corporate Outlook

Abivax Provides 2026 Corporate Outlook Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD spaceABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025, found no new safety signals with over 80% of participants having completed the 44-week double blind maintenance trialABTECT-UC Phase 3 maintenance topline results expected late Q2 2026, with a subsequent US regulatory filing planned for late 2026ENHANCE-CD ...

January 7, 2026 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax to be Added to Nasdaq Biotechnology Index

Abivax to be Added to Nasdaq Biotechnology Index Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. Didie...

December 18, 2025 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in I...

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, and cytokine data from the Phase 3 ABTE...

December 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch